๐๐จ๐ซ๐ฐ๐๐ฒ has issued a positive reimbursement recommendation for ๐๐๐๐๐๐๐๐® (etranacogene dezaparvovec)—an ๐๐๐5-๐๐๐ฌ๐๐ ๐ ๐๐ง๐ ๐ญ๐ก๐๐ซ๐๐ฉ๐ฒ ๐๐จ๐ซ ๐ก๐๐๐ฆ๐จ๐ฉ๐ก๐ข๐ฅ๐ข๐ ๐, developed by CSL Behring.
Key highlights:
๐ฌ One-time AAV gene therapy enabling sustained Factor IX expression
๐ ~90% reduction in bleeding rates (HOPE-B Phase III data)
๐ 94% of patients off prophylaxis at 5 years
๐งช Effective even in patients with pre-existing AAV5 antibodies
This marks another step forward in the shift from chronic treatment to durable genetic solutions—with AAV continuing to lead the way in rare disease innovation.
๐๐
๐จ๐ฅ๐ฅ๐จ๐ฐ PackGene ๐จ๐ง ๐๐ข๐ง๐ค๐๐๐ข๐ง & ๐๐ฎ๐๐ฌ๐๐ซ๐ข๐๐ ๐ญ๐จ ๐๐ฎ๐ซ ๐๐๐ฐ๐ฌ๐ฅ๐๐ญ๐ญ๐๐ซ ๐๐จ๐ซ ๐๐๐๐ค๐ฅ๐ฒ ๐๐๐ ๐๐ฉ๐๐๐ญ๐๐ฌ: https://lnkd.in/eS-3XyZ3
AAV GeneTherapy Hemophilia RareDisease Biotech ClinicalTrials
๐งฌ ๐๐๐ ๐ ๐๐ง๐ ๐ญ๐ก๐๐ซ๐๐ฉ๐ฒ ๐ฆ๐ข๐ฅ๐๐ฌ๐ญ๐จ๐ง๐ ๐ข๐ง ๐๐ฎ๐ซ๐จ๐ฉ๐
Mar 17, 2026
Norway Recommends Reimbursement of AAV Gene Therapy for Haemophilia B